Tunis, Tunisia

Erij Messadi

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Institut Pasteur De Tunis, National Institute of Health and Medical Research. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erij Messadi. Retrieved from https://idiyas.com/inventor/erij-messadi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Erij Messadi: Innovator in Neovascularization Inhibition

Introduction

Erij Messadi is a notable inventor based in Tunis, Tunisia. He has made significant contributions to the field of medical research, particularly in the area of neovascularization. His work focuses on developing innovative solutions for treating various neovascular diseases.

Latest Patents

Erij Messadi holds a patent for Lebecetin, a C-type lectin, which serves as a neovascularization inhibitor. This invention is particularly relevant in the treatment of neovascular diseases such as ocular diseases, cancers, and inflammatory disorders that have a neovascular component. The functional variant or fragment of Lebecetin showcases its potential in addressing critical health issues.

Career Highlights

Throughout his career, Erij Messadi has worked with esteemed institutions, including Sorbonne University and the Centre National de la Recherche Scientifique. His experience in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

Erij has collaborated with notable colleagues, including Xavier Guillonneau and Fadoua Montassar. These partnerships have enriched his research endeavors and fostered innovation in his field.

Conclusion

Erij Messadi's work in developing Lebecetin as a neovascularization inhibitor highlights his commitment to advancing medical science. His contributions are vital in the ongoing fight against neovascular diseases, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…